Adverse effects of intraoperative blood loss on long-term outcomes after curative gastrectomy of patients with Stage II/III gastric cancer

Digestive Surgery

Volumn 33, Issue 2, 2016, Pages 121-128

  Mizuno, Akira ^a   Kanda, Mitsuro ^a   Kobayashi, Daisuke ^a   Tanaka, Chie ^a   Iwata, Naoki ^a   Yamada, Suguru ^a   Fujii, Tsutomu ^a   Nakayama, Goro ^a   Sugimoto, Hiroyuki ^a   Koike, Masahiko ^a   Fujiwara, Michitaka ^a   Kodera, Yasuhiro ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Adjuvant chemotherapy; Blood loss; Gastric cancer; Prognosis

Indexed keywords

ADULT; AGED; CANCER STAGING; FEMALE; FOLLOW UP; GASTRECTOMY; HUMAN; LYMPH NODE DISSECTION; MALE; METASTASIS; MIDDLE AGED; MORTALITY; OPERATIVE BLOOD LOSS; PATHOLOGY; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BLOOD LOSS, SURGICAL; FEMALE; FOLLOW-UP STUDIES; GASTRECTOMY; HUMANS; LYMPH NODE EXCISION; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; ROC CURVE; STOMACH NEOPLASMS; SURVIVAL ANALYSIS;

EID: 84954456750     PISSN: 02534886     EISSN: None     Source Type: Journal    
DOI: 10.1159/000443219     Document Type: Article

References (31)

1. Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ. Gastric cancer. Lancet 2009; 374: 477-490.
2. Kanda M, Shimizu D, Nomoto S, Takami H, Hibino S, Oya H, Hashimoto R, Suenaga M, Inokawa Y, Kobayashi D, Tanaka C, Yamada S, Fujii T, Nakayama G, Sugimoto H, Koike M, Fujiwara M, Kodera Y. Prognostic impact of expression and methylation status of DENN/MADD domain-containing protein 2D in gastric cancer. Gastric Cancer 2015; 18: 288-296.
3. Shen L, Shan YS, Hu HM, Price TJ, Sirohi B, Yeh KH, Yang YH, Sano T, Yang HK, Zhang X, Park SR, Fujii M, Kang YK, Chen LT. Management of gastric cancer in Asia: resourcestratified guidelines. Lancet Oncol 2013; 14: e535-E547.
4. Kanda M, Nomoto S, Oya H, Takami H, Shimizu D, Hibino S, Hashimoto R, Kobayashi D, Tanaka C, Yamada S, Fujii T, Nakayama G, Sugimoto H, Koike M, Fujiwara M, Kodera Y. The expression of melanoma-Associated antigen D2 both in surgically resected and serum samples serves as clinically relevant biomarker of gastric cancer progression. Ann Surg Oncol 2015, Epub ahead of print.
5. Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide dutch D1D2 trial. Lancet Oncol 2010; 11: 439-449.
6. Kanda M, Kodera Y, Sakamoto J. Updated evidence on adjuvant treatments for gastric cancer. Expert Rev Gastroenterol Hepatol 2015; 9: 1-12.
7. Nagai S, Fujii T, Kodera Y, Kanda M, Sahin TT, Kanzaki A, Yamada S, Sugimoto H, Nomoto S, Takeda S, Morita S, Nakao A. Impact of operative blood loss on survival in invasive ductal adenocarcinoma of the pancreas. Pancreas 2011; 40: 3-9.
8. Morner ME, Gunnarsson U, Jestin P, Svanfeldt M. The importance of blood loss during colon cancer surgery for long-Term survival: an epidemiological study based on a population based register. Ann Surg 2012; 255: 1126-1128.
9. Kanda M, Kobayashi D, Tanaka C, Iwata N, Yamada S, Fujii T, Nakayama G, Sugimoto H, Koike M, Nomoto S, Murotani K, Fujiwara M, Kodera Y. Adverse prognostic impact of perioperative allogeneic transfusion on patients with stage II/III gastric cancer. Gastric Cancer 2016; 19: 255-263.
10. Sobin LH, Gospodarowicz MK, Wittekind C. International Union Against Cancer; TNM Classification of Malignant Tumors, ed 7. New York, Wiley-Blackwell, 2009.
11. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer 2011; 14: 113-123.
12. Kanda M, Shimizu D, Fujii T, Sueoka S, Tanaka Y, Ezaka K, Takami H, Tanaka H, Hashimoto R, Iwata N, Kobayashi D, Tanaka C, Yamada S, Nakayama G, Sugimoto H, Koike M, Fujiwara M, Kodera Y. Function and diagnostic value of Anosmin-1 in gastric cancer progression. Int J Cancer 2016; 138: 721-730.
13. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K; ACTS-GC Group. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007; 357: 1810-1820.
14. Kanda M, Oya H, Nomoto S, Takami H, Shimizu D, Hashimoto R, Sueoka S, Kobayashi D, Tanaka C, Yamada S, Fujii T, Nakayama G, Sugimoto H, Koike M, Fujiwara M, Kodera Y. Diversity of clinical implication of B-cell translocation gene 1 expression by histopathologic and anatomic subtypes of gastric cancer. Dig Dis Sci 2015; 60: 1256-1264.
15. Dhar DK, Kubota H, Tachibana M, Kotoh T, Tabara H, Watanabe R, Kohno H, Nagasue N. Long-Term survival of transmural advanced gastric carcinoma following curative resection: multivariate analysis of prognostic factors. World J Surg 2000; 24: 588-593; discussion 593-594.
16. Kamei T, Kitayama J, Yamashita H, Nagawa H. Intraoperative blood loss is a critical risk factor for peritoneal recurrence after curative resection of advanced gastric cancer. World J Surg 2009; 33: 1240-1246.
17. Liang YX, Guo HH, Deng JY, Wang BG, Ding XW, Wang XN, Zhang L, Liang H. Impact of intraoperative blood loss on survival after curative resection for gastric cancer. World J Gastroenterol 2013; 19: 5542-5550.
18. Kanda M, Kodera Y. Recent advances in the molecular diagnostics of gastric cancer. World J Gastroenterol 2015; 21: 9838-9852.
19. Aoyama T, Yoshikawa T, Hayashi T, Kuwabara H, Mikayama Y, Ogata T, Cho H, Tsuburaya A. Risk factors for peritoneal recurrence in stage II/III gastric cancer patients who received S-1 adjuvant chemotherapy after D2 gastrectomy. Ann Surg Oncol 2012; 19: 1568-1574.
20. GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group, Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon JP, Rougier P, Sakamoto J, Sargent D, Sasako M, Van Cutsem E, Buyse M. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-Analysis. JAMA 2010; 303: 1729-1737.
21. Kanda M, Nomoto S, Oya H, Shimizu D, Takami H, Hibino S, Hashimoto R, Kobayashi D, Tanaka C, Yamada S, Fujii T, Nakayama G, Sugimoto H, Koike M, Fujiwara M, Kodera Y. Dihydropyrimidinase-like 3 facilitates malignant behavior of gastric cancer. J Exp Clin Cancer Res 2014; 33: 66.
22. Aoyama T, Yoshikawa T, Watanabe T, Hayashi T, Ogata T, Cho H, Tsuburaya A. Macroscopic tumor size as an independent prognostic factor for stage II/III gastric cancer patients who underwent D2 gastrectomy followed by adjuvant chemotherapy with S-1. Gastric Cancer 2011; 14: 274-278.
23. Csendes A, Burdiles P, Rojas J, Braghetto I, Diaz JC, Maluenda F. A prospective randomized study comparing D2 total gastrectomy versus D2 total gastrectomy plus splenectomy in 187 patients with gastric carcinoma. Surgery 2002; 131: 401-407.
24. Yoo CH, Noh SH, Shin DW, Choi SH, Min JS. Recurrence following curative resection for gastric carcinoma. Br J Surg 2000; 87: 236-242.
25. Migita K, Takayama T, Saeki K, Matsumoto S, Wakatsuki K, Enomoto K, Tanaka T, Ito M, Kurumatani N, Nakajima Y. The prognostic nutritional index predicts long-Term outcomes of gastric cancer patients independent of tumor stage. Ann Surg Oncol 2013; 20: 2647-2654.
26. Zhou HY, Yi W, Wang J, Zhang J, Wang WJ, Hu ZQ. Association of perioperative allogeneic blood transfusions and prognosis of patients with gastric cancer after curative gastrectomy. Am J Surg 2014; 208: 80-87.
27. Pacelli F, Rosa F, Marrelli D, Pedrazzani C, Bossola M, Zoccali M, Marchet A, Di Cosmo M, Roata C, Graziosi L, Cavazzoni E, Covino M, D Ugo D, Roviello F, Nitti D, Doglietto GB. Do perioperative blood transfusions influence prognosis of gastric cancer patients? Analysis of 927 patients and interactions with splenectomy. Ann Surg Oncol 2011; 18: 1615-1623.
28. Kanda M, Fujii T, Kodera Y, Nagai S, Takeda S, Nakao A. Nutritional predictors of postoperative outcome in pancreatic cancer. Br J Surg 2011; 98: 268-274.
29. Bruns CJ, Schafer H, Wolfgarten B, Engert A: [Effect of intraoperative blood loss on the function of natural killer cells in tumors of the upper gastrointestinal tract]. Langenbecks Arch Chir Suppl Kongressbd 1996; 113: 146-149.
30. Tokunaga M, Tanizawa Y, Bando E, Kawamura T, Terashima M. Poor survival rate in patients with postoperative intra-Abdominal infectious complications following curative gastrectomy for gastric cancer. Ann Surg Oncol 2013; 20: 1575-1583.
31. Kanda M, Murotani K, Kobayashi D, Tanaka C, Yamada S, Fujii T, Nakayama G, Sugimoto H, Koike M, Fujiwara M, Kodera Y. Postoperative adjuvant chemotherapy with S-1 alters recurrence patterns and prognostic factors among patients with stage II/III gastric cancer: a propensity score matching analysis. Surgery 2015; 158: 1573-1580.